Abstract

Lamivudine (3TC) and zidovudine (AZT) are antiviral agents used orally to manage HIV/AIDS infection. A pseudo one-solvent bottom-up approach was used to develop and produce nano co-crystals of 3TC and AZT. Equimolar amounts of 3TC dissolved in de-ionized water and AZT in methanol were rapidly injected into a pre-cooled vessel and sonicated at 4 °C. The resultant suspensions were characterized using a Zetasizer. The particle size, polydispersity index and Zeta potential were elucidated. Further characterization was undertaken using powder X-ray diffraction, Raman spectroscopy, Fourier transform infrared spectroscopy, differential scanning calorimetry, and energy dispersive X-ray spectroscopy scanning electron microscopy. Different surfactants were assessed for their ability to stabilize the nano co-crystals and for their ability to produce nano co-crystals with specific and desirable critical quality attributes (CQA) including particle size (PS) < 1000 nm, polydispersity index (PDI) < 0.500 and Zeta potential (ZP) < −30 mV. All surfactants produced co-crystals in the nanometer range. The PDI and PS are concentration-dependent for all nano co-crystals manufactured while only ZP was within specification when sodium dodecyl sulfate was used in the process.

Highlights

  • More than 7000 people worldwide die of HIV-related causes daily

  • The micro co-crystals produced were used as reference material in the characterization experiments in order to elucidate the characteristics of nano co-crystal formation in this investigation

  • Tgrhoewctohnrtaritbeuinticorneatsoes ZPwirtehduicntciroenasaipnpgeasrusrtfoacbtaenatn caonntacgenotnriasttiiocnc,onrecesunlttriantgioni-ndespmenaldleerntdreimlaetinosnioshnisp awnidth tnhaerraonwionsiicze sudrifsatcrtibanuttiSoDnsS[.6A9n,70in].crease in sodium dodecyl sulfate (SDS) concentration resulted in lower Zeta potential (ZP) which would, result iTnhaenuesxepoefcttehde iannciroenaiscesiunrsfaoclutatniotnSsDtaSbpilriotyduofcethdectreycshtanloslowgiyth. a low ZP

Read more

Summary

Introduction

More than 7000 people worldwide die of HIV-related causes daily. Many people are not benefiting fully from the use of orally administered antiretroviral (ARV) drugs, which provide the only effective means of halting the progression of HIV disease and AIDS [1]. Eight million of the estimated 37 million HIV-positive people should be treated, but only two million are currently receiving ARV therapy. This unmet need is expected to increase on an annual basis [1]. Crystal engineering is described as the exploitation of non-covalent interactions between molecular or ionic components for the rational design of solid-state materials [2,3]. The application of crystal engineering in pharmaceutics is usually related to understanding polymorphism and its associated properties

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call